R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
NCT01133158 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61
Last updated 2018-11-01
Summary
Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- DRUG
-
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone
Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
Sponsors & Collaborators
-
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
lead OTHER
Principal Investigators
-
Francisco Javier Peñalver Párraga, MD · Hospital Universitario Fundación Alcorcón
-
Javier De la Serna Torroba, MD · Hospital 12 de Octubre
-
Francisca Oña Compan, MD · Hospital de Getafe.
-
Patricia Font López, MD · Gregorio Marañón Hospital
-
Secundino Ferrer Bordas, MD · Hospital Dr. Peset
-
José Ramón Mayans Ferrer, MD · Hospital Arnau de Vilanova
-
Eulogio Conde García, MD · Hospital Marqués de Valdecilla
-
José Antonio Márquez Navarro, MD · Hospital de Basurto
-
Ernesto Pérez Persona, MD · Hospital Txagorritxu
-
Garazi Letamendi Madariaga, MD · Hospital de Galdakao
-
Pilar Giraldo Castellanos, MD · Hospital Miguel Servet
-
Luis Palomera Bernal, MD · Hospital Clínico de Zaragoza
-
Andrés López Hernández, MD · Hospital Vall d´Hebron
-
Blanca Sánchez González, MD · Hospital del Mar
-
José Luis Sánchez-Majado, MD · Hospital San Juan de Alicante
-
Antonio Gutiérrez García, MD · Hospital Son Espases
-
Francisco Javier Capote Huelva, MD · Hospital Universitario Puerta del Mar
-
Fátima de la Cruz, MD · Hospital Virgen del Rocío
-
Mª José Ramírez, MD · Hospital de Jerez
-
Fernando Carnicero González, MD · Hospital San Pedro de Alcantara
-
Mª José Rodríguez Salazar, MD · Hospital Universitario de Canarias
-
Miguel Ángel Canales Albendea, MD · Hospital La Paz
-
José Antonio García Marco, MD · Hospital Puerta de Hierro
-
Carlos Montalbán Sanz, MD · Hospital Universitario Ramon y Cajal
-
Rosalía Riaza Grau, MD · Hospital Severo Ochoa
-
Mª Dolores Caballero Barrigón, MD · Hospital de Salamanca
-
Mª Jesús Peñarrubia Ponce, MD · Hospital Río Hortega
-
José Antonio Queizán, MD · Hospital de Segovia
-
Roberto Hernández Martín, MD · Hospital Virgen de la Concha
-
Mª José Terol Castera, MD · Hospital Clínico de Valencia
-
Félix Carbonell, MD · Hospital General Universitario de Valencia
-
María Rosario Varela Gómez, MD · Complejo Hospitalario A Coruña
-
José Luis Bello López, MD · C. H. U. Santiago
-
Carlos Panizo, MD · Clínica Universitaria de Navarra
-
Juan Manuel Sancho Cia, MD · Germans Trias i Pujol Hospital
-
Armando López Guillermo, MD · Hospital Clínic i Provincial
-
Elena Pérez Ceballos, MD · Hospital Morales Meseguer
-
Andrés Sánchez Salinas, MD · Hospital Universitario Virgen de la Arrixaca
-
Mª Soledad Durán Nieto, MD · Hospital de Jaén
-
Manuel Espeso de Haro, MD · Hospital Carlos Haya
-
Joan Bargay Lleonart, MD · Hospital Son Llàtzer
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2013-12-31
- Completion
- 2016-07-31
Countries
- Spain
Study Locations
More Related Trials
-
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
NCT04433182 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT02281279 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
NCT02267915 ·Status: UNKNOWN ·Phase: PHASE2
-
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
NCT01737177 ·Status: COMPLETED ·Phase: PHASE2
-
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00831597 ·Status: COMPLETED ·Phase: PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
NCT00783367 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
NCT01124526 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
NCT05245656 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
NCT00556127 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
NCT00169208 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936 ·Status: RECRUITING ·Phase: PHASE3
-
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT06834373 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005589 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 ·Status: COMPLETED ·Phase: PHASE1
-
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879 ·Status: COMPLETED ·Phase: PHASE2
-
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
NCT00992134 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT00867529 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
NCT01449344 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
NCT02099292 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292 ·Status: COMPLETED ·Phase: PHASE2